These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 22863764)

  • 1. Predicted effects of treatment for HCV infection vary among European countries.
    Deuffic-Burban S; Deltenre P; Buti M; Stroffolini T; Parkes J; Mühlberger N; Siebert U; Moreno C; Hatzakis A; Rosenberg W; Zeuzem S; Mathurin P
    Gastroenterology; 2012 Oct; 143(4):974-85.e14. PubMed ID: 22863764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chronic hepatitis C].
    Grammatikos G; Sarrazin C
    Dtsch Med Wochenschr; 2010 Dec; 135(50):2525-34; quiz 2535-8. PubMed ID: 21140330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C and hepatitis B-related mortality in Spain.
    García-Fulgueiras A; García-Pina R; Morant C; García-Ortuzar V; Génova R; Alvarez E
    Eur J Gastroenterol Hepatol; 2009 Aug; 21(8):895-901. PubMed ID: 19357523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.
    Giannini EG; Marenco S; Fazio V; Pieri G; Savarino V; Picciotto A
    Liver Int; 2012 Aug; 32(7):1113-9. PubMed ID: 22471814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France.
    Larsen C; Bousquet V; Delarocque-Astagneau E; Pioche C; Roudot-Thoraval F; ; ; Desenclos JC
    J Med Virol; 2010 Oct; 82(10):1647-54. PubMed ID: 20827760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan.
    Lai MY
    Intervirology; 2006; 49(1-2):91-5. PubMed ID: 16166795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
    Pramoolsinsap C; Poovorawan Y; Sura T; Theamboonlers A; Busagorn N; Kurathong S
    Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):480-90. PubMed ID: 10437943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of hepatitis C virus infection in Korea.
    Suh DJ; Jeong SH
    Intervirology; 2006; 49(1-2):70-5. PubMed ID: 16166792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis and treatment of chronic hepatitis C. Practical recommendations and new developments].
    Niederau C
    Med Klin (Munich); 2001 Oct; 96(10):599-607. PubMed ID: 11715332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New trends in hepatitis C management.
    Mallet V; Vallet-Pichard A; Pol S
    Presse Med; 2010 Apr; 39(4):446-51. PubMed ID: 20074903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
    Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimates on HCV disease burden worldwide - filling the gaps.
    Wedemeyer H; Dore GJ; Ward JW
    J Viral Hepat; 2015 Jan; 22 Suppl 1():1-5. PubMed ID: 25560838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C and hepatocellular carcinoma.
    Fassio E
    Ann Hepatol; 2010; 9 Suppl():119-22. PubMed ID: 20714008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?
    Deuffic-Burban S; Boursier J; Leroy V; Yazdanpanah Y; Castera L; Mathurin P
    J Hepatol; 2017 Feb; 66(2):304-312. PubMed ID: 27743987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.